Nevertheless, studies revealed that IFNG promotes tumor immune evasion by upregulating PD-L1 in a JAK-STAT pathway-dependent manner, implying that tumors characterized by increased IFNG response may be sensitive to immune checkpoint blockade therapy (4, 8, 9, 41). The gene discussed is SOAT1; the disease is neoplasm.